DNA RNA and Cells

27 May 2014

uniQure Announces Successful Transfection of Liver Cells with AAV5 and Strong Safety Data from Acute Intermittent Porphyria Clinical Trial

23 May 2014

ZIOPHARM Announces Oral Presentation Highlighting Ad-RTS-IL-12 Results Correlated With Reducing Cancer Stem Cells in the Brain at ASGCT 17th Annual Meeting

22 May 2014

Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx in the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery

22 May 2014

Asterias Biotherapeutics, Inc. Announces New Results From First-in-Man Clinical Trial of a Cell Therapy Derived From Embryonic Stem Cells

22 May 2014

Tekmira Presents Positive Interim Results on Phase I/II Clinical Programs

21 May 2014

Alnylam and Collaborators Publish Pre-Clinical Results with ALN-AS1, an RNAi Therapeutic Targeting Aminolevulinic Acid Synthase-1 (ALAS-1) for the Treatment of Hepatic Porphyrias, in the Proceedings of the National Academy of Sciences

20 May 2014

Isis Pharmaceuticals Initiates Phase 1 Study of ISIS-PKK Rx

20 May 2014

Novartis announces exclusive agreement to extend leadership in ophthalmology, leveraging novel anti-PGDF therapy Fovista

19 May 2014

Juventas Therapeutics Data Demonstrates Significant Structural, Clinically Meaningful Benefit in Patients with Advanced Heart Failure

16 May 2014

Transgene Reports Progress with its Proprietary Oncolytic Immunotherapy to Treat Solid Tumors

14 May 2014

Isis Pharmaceuticals Reports Phase 2 Data on ISIS-GCGR Rx Showing Significant Reduction in HbA1c in Patients With Type 2 Diabetes

14 May 2014

Coronado Biosciences Initiates Phase 2a Clinical Study of TSO in Pediatric Patients With Autism Spectrum Disorder

13 May 2014

Alnylam Reports Initial Positive Top-Line Data from Phase 1 Clinical Trial with ALN-AT3, an RNAi Therapeutic Targeting Antithrombin (AT) in Development for the Treatment of Hemophilia and Rare Bleeding Disorders (RBD)

12 May 2014

Alnylam Announces New RNAi Therapeutic Program for the Treatment of Hepatitis B Virus (HBV) Infection and Reports an Up to 2.3 Log10 Reduction of HBV Surface Antigen (HBsAg) in Chronically Infected Chimpanzees

12 May 2014

Gene Signal announces positive data from Phase III trial of aganirsen eye drops for corneal neovascularisation due to inflammation, a rare eye disease with European Orphan Drug designation

8 May 2014

Marina Biotech Presents Clinical Data Demonstrating Delivery of Both Single and Double-Stranded Nucleic Acids to Tumors

6 May 2014

Alnylam Advances Development Candidate for ALN-AAT, a Subcutaneously Administered RNAi Therapeutic Targeting Alpha-1 Antitrypsin (AAT) in Development for the Treatment of AAT Deficiency-Associated Liver Disease

6 May 2014

CYTOMEDIX ANNOUNCES RESULTS OF RECOVER-STROKE PHASE 2 STUDY; PROVIDES UPDATE ON R&D REORGANIZATION AND ONGOING LAUNCH INITIATIVES FOR AUTOLOGELT

5 May 2014

MOLOGEN AG: Submission of international pivotal study IMPALA with MGN1703 in colorectal cancer initiated

5 May 2014

MolMed reports top line results of NGR-hTNF in the phase III trial in malignant pleural mesothelioma

2 May 2014

Isis Reports Final Phase 2 Data on ISIS-APOCIII Rx in Patients With Familial Chylomicronemia

2 May 2014

RXi Pharmaceuticals Announces Positive Results with RXI-109 in the Eyes of Cynomolgus Monkeys as Part of a Dose Range Finding Study

1 May 2014

Isis Reports Final Phase 2 Data on ISIS-APOCIII Rx in Patients With High Triglycerides and Type 2 Diabetes

29 April 2014

RXi Pharmaceuticals Announces Initiation of Phase 2a Keloid Study

29 April 2014

REGENX Biosciences Enters Into License Agreement With AAVLife for Development of Treatments for Friedreich’s Ataxia Using NAV(R) Vectors

28 April 2014

Athersys Announces Results From Phase 2 Study of MultiStem(R) Cell Therapy for Ulcerative Colitis

28 April 2014

Alnylam and Collaborators Present New Clinical Data for Patisiran, an RNAi Therapeutic Targeting Transthyretin (TTR) in Development for the Treatment of TTR-Mediated Amyloidosis (ATTR)

28 April 2014

OncoGenex Announces Top-Line Survival Results of Phase 3 SYNERGY Trial Evaluating Custirsen for Metastatic Castrate-Resistant Prostate Cancer

28 April 2014

Successful safety trial with MGN1703 in the U.S.

24 April 2014

Celgene Acquires Late-Stage Product for Crohn’s Disease and Other Gastrointestinal Disorders

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Ustekinumab (Stelara) Biosimilars Pipeline Review

Claudin 18.2-Targeted Immunotherapeutics – a Competitor Analysis

Blockbuster Biologics 2017: Sales of Recombinant Therapeutic Antibodies & Proteins

Claudin 18.2-Targeted Immunotherapy: a landscape analysis of stakeholders, drug modalities, pipeline and business opportunities from an industry perspective

Report Package: Claudin 18.2-Targeted Immunotherapeutics

Fibroblast Activation Protein (FAP) Targeted Therapy & Companion Diagnostic Pipeline Review

Claudin 6: A target opportunity to develop effector-enhanced drug modalities

Aflibercept (Eylea) Biosimilars Pipeline Review

RNA-Targeted Novel Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting & More: a landscape analysis of technologies, targets, business and financing from an industry perspective

CD73 Inhibitor Pipeline Review